http://54.88.27.110/in-the-news/viral-variants-and-vaccine-nationalism-pose-two-pronged-threat-to-covid-victory/http://54.88.27.110/in-the-news/africas-need-for-a-dedicated-covid-19-vaccine-supply/http://54.88.27.110/in-the-news/akston-biosciences-launches-phase-i-ii-clinical-trial-of-second-generation-covid-19-vaccine/http://54.88.27.110/in-the-news/small-local-biotechs-make-progress-on-their-own-covid-19-drugs/http://54.88.27.110/in-the-news/second-gen-vaccines-could-hold-key-to-vanquishing-virus/http://54.88.27.110/in-the-news/2928/http://54.88.27.110/in-the-news/waiving-vaccine-ip-protections-will-do-more-harm-than-good/http://54.88.27.110/in-the-news/second-generation-vaccines-the-next-stage-ofcoronavirus-recovery/http://54.88.27.110/in-the-news/the-right-shots-in-the-right-places/http://54.88.27.110/in-the-news/how-and-how-not-to-vaccinate-the-whole-world/http://54.88.27.110/in-the-news/amid-surging-covid-19-cases-second-gen-vaccines-raise-hopes-across-the-asia-pacific/http://54.88.27.110/in-the-news/tested-in-groningen-easy-to-produce-akston-vaccine-should-help-vaccinate-poorer-countries-quickly/http://54.88.27.110/in-the-news/second-generation-vaccines-crucial-to-beating-pandemic-around-the-world/http://54.88.27.110/in-the-news/new-vaccines-should-help-india-fill-gaps-in-vaccination-campaign/http://54.88.27.110/in-the-news/beverly-biotech-shows-promising-covid-vaccine-data-raises-19-5m/http://54.88.27.110/in-the-news/vaccination-program-in-india-stalls-as-nation-faces-deadly-third-wave/http://54.88.27.110/in-the-news/todd-zion-phd-ceo-and-repeat-founder-magical-proteins/http://54.88.27.110/in-the-news/could-second-generation-vaccines-accelerate-africas-slow-immunisation-drive/http://54.88.27.110/in-the-news/business-mrna-deals-will-not-solve-africas-vaccine-shortfall-but-the-second-generation-of-vaccines-may/http://54.88.27.110/in-the-news/second-wave-of-covid-19-vaccines-could-resolve-vaccine-inequity/http://54.88.27.110/in-the-news/more-accessible-covid-19-vaccines-and-community-engagement-key-for-rural-areas/http://54.88.27.110/in-the-news/in-the-pipeline-what-the-next-wave-of-covid-19-vaccines-could-look-like/http://54.88.27.110/in-the-news/second-generation-vaccines-offer-a-chance-to-correct-flaws-in-early-vaccination-campaigns/http://54.88.27.110/in-the-news/the-next-covid-challenge-building-an-arsenal-of-vaccines/http://54.88.27.110/in-the-news/vaccinating-the-world-the-effort-to-get-covid-vaccines-to-everyone/http://54.88.27.110/in-the-news/looking-forward-to-second-gen-vaccines-says-who-chief-from-nasal-sprays-to-multivariant-jabs-vaccines-in-development-spur-hope-of-ending-the-pandemic/http://54.88.27.110/in-the-news/akston-begins-trials-for-room-temperature-covid-shot-as-next-generation-vaccine-race-heats-up/http://54.88.27.110/in-the-news/what-will-tomorrows-covid-19-vaccines-be-like/http://54.88.27.110/in-the-news/akston-biosciences-seeks-usd-10m-25m-raise-plans-for-further-covid-19-vaccine-booster-trials/http://54.88.27.110/in-the-news/easier-to-produce-room-temperature-covid-shot-shows-promise-in-early-clinical-trials/http://54.88.27.110/in-the-news/2nd-generation-covid-19-vaccine-available-in-130-countries/http://54.88.27.110/in-the-news/stelis-licenses-akstons-aks-452-thermostable-protein-subunit-covid-vax/http://54.88.27.110/in-the-news/akston-biosciences-and-biolexis-collaborate-to-launch-a-room-temperature-stable-2nd-generation-covid-19-vaccine-in-130-countries/http://54.88.27.110/in-the-news/akston-biosciences-and-biolexis-enter-covid-19-vaccine-partnership/http://54.88.27.110/in-the-news/will-the-second-wave-of-covid-19-vaccines-have-the-improved-properties-needed-to-end-the-pandemic/http://54.88.27.110/in-the-news/covid-19-vaccine-akston-biosciences-doses-first-volunteers-in-phase-ii-iii-trial/http://54.88.27.110/in-the-news/achieving-vaccine-equality-is-key-to-overcoming-covid/http://54.88.27.110/in-the-news/getting-through-the-corona-pandemic-with-aks-452-vaccines/http://54.88.27.110/in-the-news/akston-biosciences-raising-up-to-usd-10m-to-advance-covid-19-vaccine-and-other-products-ceo-says/http://54.88.27.110/in-the-news/why-indian-pharma-must-evolve-as-value-creator/http://54.88.27.110/in-the-news/strides-pharma-jumps-on-positive-outcome-of-covid-19-vaccine-trials/http://54.88.27.110/in-the-news/dechra-pharmaceuticals-achieves-strong-organic-growth-in-all-key-markets/http://54.88.27.110/in-the-news/akston-starts-small-and-likes-it-that-way/